Journal article
Resistance to RAF Inhibitors Revisited
Journal of investigative dermatology, v 134(2), pp 319-325
01 Feb 2014
PMID: 24108405
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF melanoma patients. It was soon evident that the response to RAF inhibitor is heterogeneous and that the short-term benefits are burdened by the development of resistance. The field has progressed rapidly with the Food and Drug Administration approval of vemurafenib and the development of other RAF and MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibitors. Despite these advances, the issue of RAF inhibitor resistance remains. Here, we review recent clinical advances in the field, the growing number of resistance mechanisms, preclinical evidence for combinatorial trials using RAF inhibitors as the building blocks, and the new challenges that are arising.
Metrics
Details
- Title
- Resistance to RAF Inhibitors Revisited
- Creators
- Edward Hartsough - Thomas Jefferson UniversityYongping Shao - Thomas Jefferson UniversityAndrew E. Aplin - Thomas Jefferson University
- Publication Details
- Journal of investigative dermatology, v 134(2), pp 319-325
- Publisher
- Elsevier
- Number of pages
- 7
- Grant note
- W81XWH-11-1-0385 / Department of Defense; United States Department of Defense R01-CA125103; R01-CA160495 / National Institutes-of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Dr Miriam and Sheldon G Adelson Medical Research Foundation R01GM067893 / NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS) R01CA125103 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) National Cancer Center Joanna M Nicolay Melanoma Foundation
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000329896000008
- Scopus ID
- 2-s2.0-84892805414
- Other Identifier
- 991020531968404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Dermatology